Therapeutic targeting of AR in prostate cancer using antiandrogens may be considerably enhanced by targeting of Stat5, through a stimulation of proteosomal degradation of AR liganded by antiandrogens [440]. The gene discussed is AR; the disease is prostate carcinoma.